Recent research in AIDS Care found that VA patients with HIV had better treatment retention and viral suppression when taking a single-tablet regimen compared with a multi-tablet regimen.
The authors of a recent study aimed to investigate the effectiveness of an emerging cardiovascular risk biomarker in predicting CVD risk specifically among patients with HIV infection.
It is currently unclear whether residual virus replication occurs in HIV-infected individuals on ART, and whether this replication could be a barrier to achieving an HIV cure.
In his latest blog, Russ J Spjut, PharmD, owner of Formulary Intel Consulting, discusses how a newly approved HIV treatment could offer hope for low adherence populations due to its low administration...
The use of second line antiretroviral therapy with ritonavir and lopinavir has increased in recent years, but at this time, little is known about the safety of tenofovir co-administration with LPV/r.
Mylan plans to improve access and increase costs savings within the $20 billion antiretroviral marketplace, by launching 2 of its HIV combination treatments—Symfi Lo and Cimduo—at a significant discount...
Neurological complications are known to be major contributors to morbidity and mortality in patients with HIV. In a recent review, researchers investigated how HIV-associated neurological complications...
The authors of a recent study compared outcomes among patients with HIV and tuberculosis who were treated with daily and intermittent antituberculosis regimens.
